3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
50
Stomach Neoplasms
7
Neoplasm Metastasis
5
Colorectal Neoplasms
4
Uterine Cervical Neoplasms
3
HER2-positive Breast Cancer
3
Esophageal Neoplasms
3
Uterine Neoplasms
2
Solid Tumors
2
Lung Neoplasms
2
Inflammatory Breast Neoplasms
2
Gallbladder Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Diseases
2
Brain Neoplasms
2
Biliary Tract Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Adenocarcinoma Of Esophagus
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Cancer
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Patient Compliance
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Interventions
Surgical Procedures, Operative
2
Paclitaxel
2
Doxorubicin
2
Cyclophosphamide
2
Carboplatin
2
pertuzumab
1
liposomal doxorubicin
1
cemiplimab
1
atezolizumab
1
Trastuzumab
1
Radiotherapy
1
Indocyanine Green
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Invasive Breast Cancer
×
Trastuzumab
×
Clear all
NCT03595592
2024-03-06
APTneo
Fondazione Michelangelo
Phase 3
Active not recruiting
650 enrolled